The BrainScope Company, Inc. is the developer of a new generation of hand-held, simple-to-use, non-invasive instruments that, unlike existing technologies, can help medical professionals and other trained users quickly, accurately and objectively assess brain function at the initial point of care, allowing patients suffering from concussions, stroke and other brain dysfunctions to be promptly guided to appropriate treatment.

BrainScope devices are based on a revolutionary, proprietary, and proven technology platform, Bx, which integrates the world’s largest database of brainwave recordings with cutting-edge developments in Digital Signal Processing (DSP), advanced algorithms, miniaturized hardware and disposable headset sensors. Bx technology has been developed through a collaborative effort led by BrainScope President and Founder Dr. Elvir Causevic, medical researchers at NYU’s Brain Research Laboratories, and a world-wide team of mathematicians, scientists and engineers at Plain Sight Systems, Inc., a developer of information extraction solutions centered at Yale University.

Our unique devices meet a long-standing need for safe, non-invasive, radiation-free, front-line tools that can assist with an initial assessment of brain function anywhere – in an ambulance or emergency department, on the sports field or the battlefield, in the hospital or the home.

History

The BrainScope Company was founded by Dr. Elvir Causevic, a Bosnian-born entrepreneur with expertise in advanced signal processing and wavelet theory and a former assistant professor of applied mathematics at Yale University. Dr. Causevic, an electrical engineer by training, is the inventor of BrainScope’s core technologies and the President of BrainScope.

The key idea behind BrainScope is that the electrical activity of the brain holds a wealth of information regarding a patient’s brain state and neurological condition – data that, until now, has largely been untapped.

BrainScope’s products, and those of an earlier company co-founded by Dr. Causevic, Everest Biomedical, are based on Bx, a technology platform developed by BrainScope and its research partners and based on patented algorithms that efficiently extract key signal features from the brain’s noisy, complex electrical activity, and employ them to assist in identifying and classifying brain dysfunction. The algorithms were developed – and continue to be refined – using the world’s largest (and still growing) database of patient records encompassing a wide range of confirmed brain pathologies.

Everest Biomedical successfully developed two Bx-based products that have already been proven on the market – the AUDIOscreener infant brain monitor, which was sold to VIASYS Healthcare (now part of Cardinal Health), and SNAP II, an intra-operative surgical monitor that was acquired by Stryker Corporation.

BrainScope’s first Bx-based product, the BrainScope NT-1000, is in clinical trials in emergency departments at three leading university hospitals (New York University, Case-Western Reserve in Cleveland, and Washington University in St. Louis); these trials are scheduled to be significantly expanded in 2008.

BrainScope products currently in the pipeline aim to not only detect abnormal brain function, but also distinguish mild from severe concussions and types of stroke, seizure and other functional impairments, and identify Alzheimer’s/dementia, depression, and other neurologically-based functional impairments.

BrainScope was incorporated in 2006, when it grew out of Everest Biomedical, which was later acquired (in 2007), along with its line of SNAP II products, by Stryker Instruments, a division of Stryker Corporation. The BrainScope Company remains privately held. It is headquartered in Saint Louis.